TIANJIN DEV (00882): Tianjin Lisheng Pharmaceutical's net profit attributable to the parent in the first quarter was 55.2753 million yuan, a decrease of 6.56% year-on-year.

TIANJIN DEV (00882) announced the performance of Tianjin Lisheng Pharmaceutical for the three months ending on March 31, 2025. The total operating income was 370 million yuan, an increase of 1.37% year-on-year. The net profit attributable to the owners of the parent company was 55.2753 million yuan, a decrease of 6.56% year-on-year. The basic earnings per share were 0.21 yuan.